Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus

Author： Papanas Nikolaos   Katsiki Niki   Hatzitolios Apostolos I   Maltezos Efstratios  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.10, 2011-07, pp. : 1457-1461

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective

By Neeser K.  

PharmacoEconomics, Vol. 22, Iss. 5, 2004-01 ,pp. : 321-341

Adis International

Access to resources Recommend Favorite

Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

By Rajagopalan R.   Perez A.   Ye Z.   Khan M.   Murray F.T.  

Drugs & Aging, Vol. 21, Iss. 4, 2004-01 ,pp. : 259-271

Adis International

Access to resources Recommend Favorite

Combination lipid therapy in type 2 diabetes mellitus

By Vergèès Bruno  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 9, 2011-06 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone combination therapy good value in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1434, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

By Bailey Clifford J   Green Brian D   Flatt Peter R  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. : 1017-1025

Informa Healthcare

Access to resources Recommend Favorite